Today marks an exciting milestone for Enzymicals AG as the Supervisory Board met in person for the first time in its new constellation following the recent change in shareholder structure.
The board now comprises:
•Prof.Uwe Bornscheuer, a globally recognized leader in biocatalysis, co-founder of Enzymicals, and a driving force behind innovation in the field.
•Prof. Dagmar Braun, physician, successful entrepreneur in the pharmaceutical industry, and recipient of the prestigious Federal Cross of Merit.
•Dr. Martin Erhardt, the newest addition of the board, a pharmacist with extensive expertise in managing pharmaceutical plants and CEO of HERBRAND PharmaChemicals GmbH.
This distinguished board will work closely with our CEO, Dr. David Liese, to guide Enzymicals AG through its next phase of growth. During today’s meeting, the board approved significant new investments to drive the company’s continued expansion and success.
We are grateful for their insights and leadership as we push forward in revolutionizing enzyme-based solutions for sustainable chemical production.
